BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, December 28, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

June 15, 2020

View Archived Issues

PharmAbcine partners with Thermo Fisher to advance PMC-309

Read More

New liver metastasis biomarker and target identified

Read More

Y220X mutations impairing the thermostability of p53 can be targeted with small-molecule stabilizers

Read More

Cullinan Oncology and PDI Therapeutics collaborate to develop CLN-619

Read More

Macrophages rewire cholesterol metabolism for bacterial toxin defense

Read More

Optimized tandem CD19/CD20 CAR-engineered T cells induce durable antitumor response

Read More

First-in-human data for FP-1305

Read More

Boehringer Ingelheim reveals phase I data for BI-836880 plus BI-754091 in NSCLC

Read More

Janus kinase inhibitors patented by Jiangsu Hansoh Pharmaceutical, Shanghai Hansoh Biomedical

Read More

Yangtze River Pharmaceutical, Shanghai Haiyan Pharmaceutical Technology describe IDO-1 inhibitors

Read More

RORC antagonists presented by Jiangsu Chia Tai Tianqing Pharmaceutical, Nanjing Gear Pharma & Tech

Read More

Harvard College and Zikani Therapeutics identify new azaketolides

Read More

Roche presents DNA gyrase and/or DNA topoisomerase IV inhibitors

Read More

MDM2 inhibitor KRT-232 shows promise in phase II study in myelofibrosis patients

Read More

Initial phase I data show promise for PKCbeta inhibitor MS-553 in R/R CLL/SLL

Read More

Sinovac releases preliminary phase I/II results for CoronaVac

Read More

ILT-101 expands and activates regulatory T cells in autoimmune/inflammatory diseases

Read More

Seattle Genetics opens enrollment in phase I study of SGN-B6A for advanced solid tumors

Read More

Carsgen initiates phase I study of AB-011 in CLDN18.2-positive advanced solid tumors

Read More

New phase I study of KRAS peptide vaccine in colorectal and pancreatic cancer

Read More

Zai Lab studies anti-CD47 antibody ZL-1201 for advanced cancer in phase I

Read More

FDA approves dispersible tablet formulation of dolutegravir for infants and children with HIV

Read More

Novartis studies MAS-825 in phase II for COVID-19

Read More

FDA approves Gardasil 9 for HPV-related oropharyngeal and head and neck cancers

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 24, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 24, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Illustration of tau accumulating in a neuron cell.

    ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug

    BioWorld
    ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing